Glyx Therapeutics to Attend BioFIT 2025 in Strasbourg
December 2025 — Amiens, France
Glyx Therapeutics will participate in BioFIT 2025, taking place in Strasbourg on December 2 and 3, 2025. As one of Europe’s leading partnering events for early-stage innovation in life sciences, BioFIT offers a direct channel to engage investors, industrial partners, and technology transfer stakeholders as Glyx advances its Seed round and prepares its lead candidate for clinical proof-of-concept.
What Is BioFIT
BioFIT is the premier European platform dedicated to technology transfer, academia-industry collaboration, and early-stage biotech partnering. Each edition brings together pharmaceutical companies, venture funds, technology transfer offices, and emerging biotechs to source and structure high-value partnering opportunities. The event combines pre-scheduled one-to-one meetings, a startup slam, an innovation exhibition, and expert-led conferences—making it a focal point for licensing discussions and investment sourcing across the sector.
Why This Event Matters for Glyx
Glyx Therapeutics is developing a first-in-class, orally available, brain-penetrant small molecule targeting the tau protein, the primary pathological driver of tauopathies and Alzheimer’s disease. With in vivo proof of concept established in the rTg4510 tauopathy mouse model, confirmed blood-brain barrier penetration, and a favorable early safety profile, the program is positioned at a key value inflection point.
BioFIT 2025 supports two strategic priorities for the company:
- Investor engagement — connecting with venture funds, business angels, and family offices to accelerate the ongoing €5M Seed round.
- Industrial partnering — initiating discussions with pharmaceutical partners around the company’s staged, indication-split licensing model, spanning rare tauopathies and Alzheimer’s disease.
Event Details
- Dates: December 2–3, 2025
- Location: Strasbourg, France
- Format: Pre-arranged one-to-one partnering meetings, conferences, and innovation exhibition
- Focus: Technology transfer, licensing, and early-stage biotech investment
Meet Us at BioFIT
Investors and partners attending BioFIT 2025 are invited to schedule a meeting with the Glyx Therapeutics team. These discussions provide an opportunity to review our preclinical data package, development roadmap toward the first in human study, and licensing strategy under confidentiality.
To arrange a meeting, contact us
We look forward to connecting with the partnering community in Strasbourg and advancing the development of differentiated therapeutic solutions for patients affected by tauopathies and Alzheimer’s disease.
